Nektar Therapeutics - Common Stock (NQ:NKTR)

43.58 UNCHANGED

Delayed Quote Updated: 4:15 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Nektar (NKTR) Q2 Revenue Falls 52% ↗

August 08, 2025

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

3 Bullish Biotech Stocks With Explosive Growth Trends ↗

July 21, 2025

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

Via MarketBeat

Why Nektar Therapeutics Stock Dived by 3% Today ↗

July 03, 2025

Via The Motley Fool

US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%...,' Says Expert ↗

July 01, 2025

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.

Via Benzinga

MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday ↗

July 01, 2025

Via Benzinga

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains ↗

June 30, 2025

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

Via MarketBeat

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

June 28, 2025

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Via MarketBeat

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside ↗

June 25, 2025

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis.

Via Stocktwits

Why Nektar Therapeutics Stock Was Red-Hot Today ↗

June 25, 2025

Via The Motley Fool

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? ↗

June 25, 2025

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 25, 2025

Via Benzinga

AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday ↗

June 25, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

June 25, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 24, 2025

Via Benzinga

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further ↗

June 24, 2025

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Via Stocktwits

Topics Economy Government

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1 ↗

June 24, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

June 24, 2025

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Which stocks are gapping on Tuesday? ↗

June 24, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings ↗

June 24, 2025

Via Benzinga

Nektar Therapeutics Shares Double On Promising Eczema Drug Data ↗

June 24, 2025

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a consistent safety profile.

Via Benzinga

Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam ↗

June 24, 2025

The company's experimental eczema drug met all the primary and secondary goals in a midstage study.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

June 24, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 24, 2025

Via Benzinga

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket ↗

June 24, 2025

Via Benzinga

US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings ↗

June 24, 2025

U.S. futures were trading higher on Tuesday after a positive day of trade on Monday. Futures of major benchmark indices were trading higher.

Via Benzinga

Topics Government

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away ↗

June 23, 2025

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Via Stocktwits

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 23, 2025

Via Benzinga

Top movers in Monday's after hours session ↗

June 23, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.